Current use of biologicals in thrombosis and haemostasis

• References

• 1 Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16: 155-165.
• 2 Crafoord C, Jorpes J. Heparin as a prophylaxis against thrombosis. J Am Med Assoc 1941; 111: 2831-2840.
• 3 Cai K, Gierman TM, Hotta J. et al. Ensuring the biologic safety of plasma-derived therapeutic proteins. Detection, inactivation and removal of pathogens. Biodrugs 2005; 19: 79-96.
• 4 Crommelin DJ, Storm G, Verrijk R. et al. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003; 266: 3-16.
• 5 Kakkar VV, Corrigan T, Spindler J. et al. Efficacy of low doses of heparin in the prevention of deep-vein thrombosis after major surgery. A double-blind, randomized trial. Lancet 1973; 2: 101-106.
• 6 Koller M, Schoch U, Buchmann P. et al. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized double-blind study versus unfractionated heparin. Thromb Haemost 1986; 56: 243-246.
• 7 Kakkar VV, Djazaeri B, Fok J. et al. Low molecular weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 1982; 284: 375-379.
• 8 Caen JP. (A French Multicenter Trial). A randomized double blind study between low molecular weight heparin (KABI 2165) and standard heparin in the prevention of deep vein thrombosis in general surgery. Thromb Haemost 1988; 59: 216-220.
• 9 The Haemophilia Society.. An introduction to haemophilia A and related bleeding disorders.. >London: the Haemophilia Society; 2004
• 10 Burnouf T, Michalsk C, Goudemand M. et al. Properties of highly purified plasma factor IX: C therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-232.
• 11 Lundblad RL, Bradshaw RA, Gabriel D. et al. A review of therapeutic uses of thrombin. Thromb Haemost 2004; 91: 851-860.
• 12 Goudemand J, Laurian Y, Calvez T. Risk of inhibitors in haemophilia and the type of factor replacement. Curr Opin Hematol 2006; 13: 316-322.
• 13 Shapiro AD, Di Paola J, Cohen A. et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518-525.
• 14 Solomon O, Seligsohn U. New observations on factor XI deficiencies. Haemophilia 2004; 10 (Suppl. 04) 184-187.
• 15 Klein HG. Pathogen inactivation technology: cleansing the blood supply. J Intern Med 2004; 257: 224-237.
• 16 Food and Drug Administration.. Guide to inspections of viral clearance processes for plasma derivatives. Available at: ww.fda.gov/org/inspect-ref/igs/viralcl.html Accessed March 2008
• 17 Takano K. Shizumek Clinical experience with somatrem in Japan. Acta Paediatr Scand Suppl 1986; 325: 19-24.
• 18 Pipe S. Recombinant clotting factors. Thromb Haemost 2008; 99: 840-850.
• 19 Gray E, Mulloy B, Barrowcliffe T. Heparin and lowmolecular- weight heparin. Thromb Haemost 2008; 99: 807-818.
• 20 Greinacher A, Warkentin T. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99: 819-829.
• 21 Warkentin T, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-839.
• 22 Ofosu F, Freedman J, Semple JW. Plasma-Derived Biological Medicines Used to Promote Haemostasis. Thromb Haemost 2008; 99: 851-862.
• 23 Wadhwa M, Thorpe R. Haematopoietic growth factors and their therapeutic use. Thromb Haemost 2008; 99: 863-873.
• 24 Mukovozov I, Sabljic TF, Hortelano G. et al. Factors that contribute to the immunogenicity of therapeutic recombinant human proteins. Thromb Haemost 2008; 99: 874-882.